Close

Citadel Securities Starts Seattle Genetics (SGEN) at Reduce; Adcetris Approvable, But Market Opportunity Appears Overestimated

August 8, 2011 7:23 AM EDT Send to a Friend
Citadel Securities initiates coverage on Seattle Genetics (NASDAQ: SGEN) with a Reduce. PT $10.00.

Citadel analyst says, "We believe the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login